Loop Diuretics
Key Points
- Loop diuretics are the most potent diuretic class — block Na-K-2Cl cotransporter in the thick ascending loop of Henle
- Furosemide (Lasix): Most commonly prescribed; treats heart failure edema, pulmonary edema, hypertension; oral onset 1 hour
- Primary adverse effects: Hypokalemia (most clinically significant), dehydration, ototoxicity (with rapid IV infusion)
- Ototoxicity risk: Administer IV furosemide slowly to prevent hearing loss
- Hypokalemia + digoxin: Hypokalemia increases digoxin toxicity risk — monitor potassium closely in patients on both
- Loop-diuretic plus lithium therapy can increase lithium levels due to reduced renal excretion.
- Administer in the morning to avoid nocturnal diuresis and sleep disruption
- In acute HF diuresis, monitor potassium and kidney function (BUN/creatinine) closely to detect AKI and electrolyte depletion early.
- Effective response trends include lower edema burden, reduced rapid weight gain, and easier breathing.
- In pediatric congenital-HF pathways, furosemide is commonly used to reduce pulmonary congestion and fluid overload with strict renal/electrolyte trending.
- In long-term pathways, loop-related calcium loss may increase fracture risk in older adults, requiring bone-health surveillance.
Drug Class Overview
Loop diuretics are the most frequently prescribed and most potent diuretic class. They are first-line treatment for edema associated with heart failure, cirrhosis, and renal disease, and are used in hypertension typically in combination with other antihypertensives. Unlike thiazide diuretics, loop diuretics retain effectiveness even when glomerular filtration rate is markedly reduced, making them the preferred diuretic in significant renal impairment.
Mechanism: Block sodium-potassium-chloride (Na-K-2Cl or NKCC2) cotransporters in the luminal membrane of the thick ascending loop of Henle → prevent reabsorption of sodium, potassium, chloride, calcium, and magnesium → significant increase in urinary output.
Major Agents
| Drug | Routes | Key Characteristics |
|---|---|---|
| Furosemide (Lasix, Furoscix) | PO, IV, IM, SC | Most commonly used; oral bioavailability ≈50%; half-life 1.5–2 hours; edema dose: 20–80 mg PO daily (max 600 mg/day); pulmonary edema: 40 mg IV; Furoscix on-body SC delivery is used in selected NYHA II/III home-heart-failure pathways when oral response is insufficient |
| Torsemide (Demadex) | PO, IV | Higher oral bioavailability (80%); longer duration 6–8 hours; initial heart-failure (heart failure) dose: 10–20 mg daily |
| Bumetanide (Bumex) | PO, IV, IM | Used when furosemide response is inadequate or high-dose escalation is needed; can be selected when ototoxicity concern exists; max 10 mg/day |
Indications
- Heart failure (systolic and diastolic): Reduces preload by decreasing circulating volume; treats pulmonary edema acutely
- Hepatic cirrhosis with ascites: Used with potassium-sparing diuretics or aldosterone antagonists
- Chronic kidney disease with fluid overload: Remains effective at lower GFR than thiazides
- Hypertension: Usually combined with other antihypertensives
- Acute pulmonary edema: IV furosemide 40 mg for emergency relief
Adverse Effects
Electrolyte Imbalances (Major Risk)
| Electrolyte | Effect | Clinical Significance |
|---|---|---|
| Potassium | Hypokalemia | Most critical; increases digoxin toxicity risk; causes muscle weakness, cardiac arrhythmias |
| Sodium | Hyponatremia | Excessive diuresis; hypovolemia |
| Calcium | Hypocalcemia | Bone health concerns with long-term use |
| Magnesium | Hypomagnesemia | Cardiac arrhythmias |
Other Adverse Effects
- Ototoxicity: Tinnitus, hearing loss — risk increases with rapid IV infusion and high doses; more common with bumetanide than furosemide
- Dehydration/Hypovolemia: Postural hypotension, dizziness, thirst, oliguria, tachycardia
- Metabolic alkalosis: From disproportionate chloride and potassium loss
- Hyperglycemia: Impaired glucose tolerance with high doses
- Hyperlipidemia and pancreatitis risk: Monitor trends in susceptible clients, especially with prior pancreatitis history.
- Rare severe reactions include anaphylactic/anaphylactoid responses, blood dyscrasias (for example thrombocytopenia, agranulocytosis, leukopenia, aplastic/hemolytic anemia), and severe dermatologic toxicity (including Stevens-Johnson syndrome).
Renal Monitoring
Monitor BUN, creatinine, and creatinine clearance — use cautiously in older adults with decreased renal function. Dose reduction may be required with renal impairment.
Nursing Assessment
Before Administration:
- Assess blood pressure, heart rate, and signs of dehydration
- Obtain baseline weight (monitor daily weight changes — report >3 lb/day gain)
- Review current potassium level — especially if patient is also on digoxin
- Assess for sulfa allergy (possible cross-reactivity with furosemide)
- Verify renal function (BUN, creatinine)
During/After Administration:
- Monitor intake and output (I&O) — document urine output carefully
- Monitor electrolytes: potassium, sodium, magnesium (especially during IV therapy)
- Trend BUN/creatinine during IV diuretic courses to detect pre-renal AKI from overdiuresis.
- IV administration: infuse slowly to prevent ototoxicity; bolus dosing is commonly given over about 1-2 minutes.
- Assess for signs of hypokalemia: muscle cramps, weakness, irregular pulse
- Assess therapeutic response as decreasing edema/weight gain and improved work of breathing.
- Monitor for orthostatic hypotension (have patient change positions slowly)
- In older adults, intensify fall-risk surveillance because orthostatic changes, urgency/nocturia, and electrolyte shifts can increase instability.
Timing:
- Administer in the morning when possible — avoid evening doses to prevent sleep disruption from nocturia
Patient Education:
- Report weight gain >3 lb in a day to provider
- Eat potassium-rich foods (bananas, oranges, potatoes, spinach) during therapy
- Avoid salt substitutes containing potassium chloride unless directed by provider (risk of hyperkalemia)
- Rise slowly from sitting/lying to prevent orthostatic hypotension
- Report muscle cramps, weakness, or irregular heartbeat immediately
- Take in the morning; avoid evening dosing
- If also taking digoxin or lithium, report nausea, confusion, arrhythmia, visual changes, or tremor promptly due to toxicity-risk interactions.
Related Concepts
- diuretics — Overview of all diuretic classes (thiazide, loop, potassium-sparing)
- fluid-volume-overload-hypervolemia — Clinical indication for loop diuretics
- potassium-balance-disorders — Hypokalemia as primary adverse effect
- heart-failure — Heart failure management with loop diuretics
- kidney-disease — Fluid management in renal disease
- anticoagulants — Monitoring of concurrent medications
Self-Check
- A patient receiving IV furosemide 40 mg is also taking digoxin 0.125 mg daily. Why is potassium monitoring especially critical in this situation?
- A nurse is preparing to administer IV furosemide 80 mg over 2 minutes. What adverse effect is this administration rate likely to cause, and how should it be prevented?
- A patient on furosemide complains of muscle cramps and weakness. Serum potassium is 3.0 mEq/L. What dietary recommendations would you provide?